AdooQ BioScience is a supplier of biochemicals located in Irvine, CA since 2006. In the past five years, we have been a renowned name engaged in manufacturing and supplying small molecule inhibitors including kinase inhibitors on kinds of signal pathway, such as PI3K, AKT, HDAC, MARP etc.
Company WebsiteXL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.
More Information Supplier PageXL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.
More Information Supplier PageXL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR).
More Information Supplier PageXL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR).
More Information Supplier PageXL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR).
More Information Supplier PageXL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR).
More Information Supplier PageXL388 is a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR).
More Information Supplier PageXL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including EGFR, HER2, ERBB2, VEGFR and EphB4.
More Information Supplier PageXL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including EGFR, HER2, ERBB2, VEGFR and EphB4.
More Information Supplier PageXL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including EGFR, HER2, ERBB2, VEGFR and EphB4.
More Information Supplier PageXL647 is an orally bioavailable small-molecule RTK inhibitor that binds to and inhibits several tyrosine receptor kinases that play major roles in tumor cell proliferation and tumor vascularization, including EGFR, HER2, ERBB2, VEGFR and EphB4.
More Information Supplier PageXL765 is a PI3K/mTOR dual kinase inhibitor and it is more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.
More Information Supplier PageXL765 is a PI3K/mTOR dual kinase inhibitor and it is more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.
More Information Supplier PageXL765 is a PI3K/mTOR dual kinase inhibitor and it is more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.
More Information Supplier PageXL765 is a PI3K/mTOR dual kinase inhibitor and it is more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.
More Information Supplier PageXL765 is a PI3K/mTOR dual kinase inhibitor and it is more potent compared to an agent that inhibits either PI3K kinase or mTOR kinase alone.
More Information Supplier PageXMD17-109 is a novel, specific inhibitor of ERK-5 with an EC50 value of 4.2 ??M in HEK293 cells.
More Information Supplier PageXMD17-109 is a novel, specific inhibitor of ERK-5 with an EC50 value of 4.2 ??M in HEK293 cells.
More Information Supplier PageXMD17-109 is a novel, specific inhibitor of ERK-5 with an EC50 value of 4.2 ??M in HEK293 cells.
More Information Supplier PageXR9576 is a P-glycoprotein inhibitor undergoing research as an adjuvant against multidrug resistance in cancer
More Information Supplier PageXR9576 is a P-glycoprotein inhibitor undergoing research as an adjuvant against multidrug resistance in cancer
More Information Supplier PageXR9576 is a P-glycoprotein inhibitor undergoing research as an adjuvant against multidrug resistance in cancer
More Information Supplier PageXY1 is a negative control of SGC 707 . SGC 707 (Adooq Catalog# A15450) is a potent, selective allosteric inhibitor of PRMT3 (IC50 = 50 nM).
More Information Supplier PageXY1 is a negative control of SGC 707 . SGC 707 (Adooq Catalog# A15450) is a potent, selective allosteric inhibitor of PRMT3 (IC50 = 50 nM).
More Information Supplier PageXY1 is a negative control of SGC 707 . SGC 707 (Adooq Catalog# A15450) is a potent, selective allosteric inhibitor of PRMT3 (IC50 = 50 nM).
More Information Supplier PageY-27632 is a Rho-Associated Coil Kinase (ROCK) inhibitor that increases the cloning efficiency of human embryonic stem cells (hESCs).
More Information Supplier PageY-27632 is a Rho-Associated Coil Kinase (ROCK) inhibitor that increases the cloning efficiency of human embryonic stem cells (hESCs).
More Information Supplier PageY-27632 is a Rho-Associated Coil Kinase (ROCK) inhibitor that increases the cloning efficiency of human embryonic stem cells (hESCs).
More Information Supplier PageY-27632 is a Rho-Associated Coil Kinase (ROCK) inhibitor that increases the cloning efficiency of human embryonic stem cells (hESCs).
More Information Supplier PageY-33075 is ROCK (Rho-associated coiled coil-forming protein kinase) inhibitor.
More Information Supplier PageY-33075 is ROCK (Rho-associated coiled coil-forming protein kinase) inhibitor.
More Information Supplier PageY-33075 is ROCK (Rho-associated coiled coil-forming protein kinase) inhibitor.
More Information Supplier PageY320 is an orally active immunomodulator, and inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 of 20 to 60 nM.
More Information Supplier PageY320 is an orally active immunomodulator, and inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 of 20 to 60 nM.
More Information Supplier PageY320 is an orally active immunomodulator, and inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 of 20 to 60 nM.
More Information Supplier PageY320 is an orally active immunomodulator, and inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 of 20 to 60 nM.
More Information Supplier PageYC-1 is a direct activator of soluble Guanylyl Cyclase (sGC), independent of Nitric Oxide.
More Information Supplier PageYC-1 is a direct activator of soluble Guanylyl Cyclase (sGC), independent of Nitric Oxide.
More Information Supplier PageYC-1 is a direct activator of soluble Guanylyl Cyclase (sGC), independent of Nitric Oxide.
More Information Supplier PageYC-1 is a direct activator of soluble Guanylyl Cyclase (sGC), independent of Nitric Oxide.
More Information Supplier Page
